Active Biotech Ab

Cantargia Ab

David Liberg

Karin Von Wachenfeldt

Kjell Sjöström

Stephen East

Natacha Prevost

Dmitry Gabrilovich

Ingela Fritzson

Colin MacKinnon

Anders Olsson

Sara Rattik

Yuliya Nefedova

Gabriel Svensson Birkedal

Camilla Rydberg Millrud

Jonathan David Hargrave

Göran Forsberg

Ulf Wellmar

Marie Bainbridge

Caitríona Grönberg

Caitriona Grönberg

Maria Ekblad

The present invention relates to antibody compositions directed to Interleukin 1 Receptor Accessory Protein (IL1RAP) and their use in the treatment and diagnosis of diseases associated with IL1RAP, such as inflammatory, autoimmune, autoinflammatory and neoplastic disorders.

Anti-IL1RAP antibody compositions

The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell. Further, it relates to the said antibody or antigen-binding fragment, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL-36γ signaling, and/or wherein the disease or disorder is associated with cells expressing IL1RAP.

Anti-IL1RAP antibody

The present invention relates to an antibody or antigen-binding fragment thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibody, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibody or antigen-binding fragment. Further, it relates to a composition comprising said antibody or antigen-binding fragment, said polynucleotide, said vector and/or said host cell. Further, it relates to the said antibody or antigen-binding fragment, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1&#x3b1;, IL-1&#x3b2;, IL-33, IL-36&#x3b1;, IL-36&#x3b2; and/or IL-36&#x3b3; signaling, and/or wherein the disease or disorder is associated with cells expressing IL1RAP.

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.

Quinoline carboxamides for use in the treatment of multiple myeloma

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.

N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma. 

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders. 

A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders. 

Growing community of inventors

Lomma, Sweden

David Liberg